Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Jason W. Denbo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3973-1738; OpenAlex author ID A5052287825. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
63
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 7 papers · 2023: 5 papers · 2024: 3 papers · 2025: 1 paper

Papers 22

  1. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17111797↗
  2. Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma: Preoperative Planning, Technical Considerations, and Building a Program. Last author DOI 10.1016/j.suc.2024.07.001↗
  3. Correction: Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.28556↗
  4. The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm13226800↗
  5. The role of minimally invasive surgery in resectable distal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2023.06.003↗
  6. The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization. Co-author DOI 10.1016/j.sopen.2023.02.001↗
  7. The association of new-onset diabetes with subsequent diagnosis of pancreatic cancer-novel use of a large administrative database. Co-author DOI 10.1093/pubmed/fdac118↗
  8. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic R… Co-author DOI 10.1177/10732748221150228↗
  9. Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.28508↗
  10. Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Last author DOI 10.1007/s00464-021-08845-9↗
  11. Patient-caregiver dyads in pancreatic cancer: identification of patient and caregiver factors associated with caregiver well-being. Co-author DOI 10.1007/s10865-022-00354-x↗
  12. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. Co-author DOI 10.1007/s11605-021-05130-x↗
  13. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation … Co-author DOI 10.1016/j.adro.2022.101045↗
  14. Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study. Co-author DOI 10.1097/as9.0000000000000197↗
  15. The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With No… Last author DOI 10.1177/10732748221109991↗
  16. Surgical Approach does not Affect Return to Intended Oncologic Therapy Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma: A Propensity-Matched St… Co-author DOI 10.1245/s10434-022-12347-w↗
  17. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  18. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. Co-author DOI 10.1002/jso.26103↗
  19. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival. Last author DOI 10.1245/s10434-019-07602-6↗
  20. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. Co-author DOI 10.1007/s11605-017-3618-4↗
  21. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Co-author DOI 10.1007/s11605-016-3286-9↗
  22. Definition and Management of Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1016/j.suc.2016.07.008↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jason B. Fleming · 15 shared papers, 2016–2025 · strength 2.27
  2. Mokenge Peter Malafa · 12 shared papers, 2020–2025 · strength 1.94
  3. Pamela Joy Hodul · 11 shared papers, 2020–2025 · strength 1.80
  4. Jessica M. Frakes · 5 shared papers, 2022–2025 · strength 0.85
  5. Sarah E. Hoffe · 5 shared papers, 2022–2025 · strength 0.85
  6. Daniel A. Anaya · 4 shared papers, 2022–2024 · strength 0.75
  7. José M. Pimiento · 5 shared papers, 2020–2025 · strength 0.75
  8. Samer A. Naffouje · 4 shared papers, 2022–2023 · strength 0.68
  9. Dae Won Kim · 4 shared papers, 2022–2025 · strength 0.61
  10. John Michael Bryant · 3 shared papers, 2022–2024 · strength 0.50
  11. Dae Won Kim · 3 shared papers, 2022–2023 · strength 0.49
  12. Jennifer B. Permuth · 3 shared papers, 2022–2023 · strength 0.43
  13. Benjamin Daniel Powers · 3 shared papers, 2020–2023 · strength 0.40
  14. Eric Hans Jensen · 3 shared papers, 2019–2023 · strength 0.40
  15. Schelomo Marmor · 3 shared papers, 2019–2023 · strength 0.40
  16. Fadi S. Dahdaleh · 2 shared papers, 2022–2023 · strength 0.38
  17. Justin A. Drake · 1 shared paper, 2024 · strength 0.31
  18. M J White · 2 shared papers, 2022–2023 · strength 0.30
  19. Christopher James LaRocca · 2 shared papers, 2022–2023 · strength 0.30
  20. Kelvin Allenson · 2 shared papers, 2022–2023 · strength 0.29
  21. Russell F. Palm · 2 shared papers, 2022–2023 · strength 0.29
  22. Joon Kyung Kim · 2 shared papers, 2020–2023 · strength 0.27
  23. Keith M. Wirth · 2 shared papers, 2019–2023 · strength 0.25
  24. Ariella M. Altman · 2 shared papers, 2019–2022 · strength 0.24
  25. Emil Lou · 2 shared papers, 2019–2022 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.